At the 5/28/26 Union County Commissioner meeting there was this resolution:
2026-392: Authorizing the County Manager to enter into an Agreement with the Frantz Law Group, APLC, San Diego, CA, to investigate and pursue litigation against manufacturers and PBMs concerning insulin and GLP-1 prescription drugs, as to damages suffered by the County of Union.
When asked why there was nothing on attorney fees County Counsel Bruce Bergen explained:
.
.
So what is this all about?
What the insulin case alleges
The core allegation is that major insulin manufacturers and PBMs used a rebate-driven pricing system that inflated list prices and shifted costs onto self-funded health plans. In the Oceanside Unified School District filing, the named defendants were Eli Lilly, Novo Nordisk, Sanofi, CVS Caremark, Express Scripts, and OptumRx, and the suit says the conduct violated state unfair-business laws and federal RICO. The theory is that PBMs demanded rebates to keep products on formularies, manufacturers raised list prices to fund those rebates, and the result was a much higher net cost for payers.
Practical significance
These suits matter because they target the pricing mechanics behind drugs that are often essential and expensive, especially for self-funded public employers and school districts. Similar claims have also drawn federal attention; the FTC sued major PBMs in 2024 over allegedly anticompetitive insulin rebate practices, which supports the broader theme of scrutiny around PBM pricing behavior. In other words, Frantz Law Group’s litigation is part of a wider wave of insulin-pricing and PBM investigations, with GLP-1 claims now appearing to be the next frontier.